Cargando…

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma

PURPOSE: To investigate the survival benefit and safety of individualized schedules for sunitinib in patients with metastatic renal cell carcinoma (mRCC) through plasma concentration monitoring. METHODS: A total of 105 patients with mRCC were enrolled. The schedule was adjusted in two ways: therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xudong, Zhang, Xingming, Sun, Guangxi, Liu, Zhenhua, Zhang, Haoran, Yang, Yaojing, Ni, Yuchao, Dai, Jindong, Zhu, Sha, Chen, Junru, Zhao, Jinge, Wang, Zhipeng, Zeng, Hao, Shen, Pengfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418361/ https://www.ncbi.nlm.nih.gov/pubmed/34512023 http://dx.doi.org/10.2147/CMAR.S327029

Ejemplares similares

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
por: Wang, Zhipeng, et al.
Publicado: (2020)

Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone
por: Zhu, Sha, et al.
Publicado: (2021)

Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma
por: Zhang, Xingming, et al.
Publicado: (2018)

The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma
por: Sun, Guangxi, et al.
Publicado: (2019)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
por: Chen, Junru, et al.
Publicado: (2022)

The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2021)

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients
por: ZHU, SHA, et al.
Publicado: (2023)

Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database
por: Chen, Junru, et al.
Publicado: (2019)

Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma
por: Zhao, Junjie, et al.
Publicado: (2022)

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8
por: Shen, Pengfei, et al.
Publicado: (2020)

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)
por: Zhu, Sha, et al.
Publicado: (2022)

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients
por: Zeng, Yuhao, et al.
Publicado: (2023)

The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study
por: Liu, Jiandong, et al.
Publicado: (2019)

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
por: Chen, Junru, et al.
Publicado: (2018)

The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy
por: Dai, Jindong, et al.
Publicado: (2019)

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients
por: Zhu, Sha, et al.
Publicado: (2021)

Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report
por: Zhu, Sha, et al.
Publicado: (2022)

The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis
por: Tao, Ronggui, et al.
Publicado: (2019)

The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs
por: Dai, Jindong, et al.
Publicado: (2020)

Sunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review
por: Zhang, Xingming, et al.
Publicado: (2018)

Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
por: Sun, Guangxi, et al.
Publicado: (2021)

The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis
por: Zhang, Xingming, et al.
Publicado: (2017)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
por: Liang, Jiayu, et al.
Publicado: (2023)

Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report
por: Zeng, Hong, et al.
Publicado: (2023)

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy
por: Zhao, Jinge, et al.
Publicado: (2017)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2017)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
por: Buti, Sebastiano, et al.
Publicado: (2018)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
por: Kang, Hee Jung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qf8604aemje8e91ig65d6nq6fb